Alphatec Holdings, Inc. (NASDAQ:ATEC) Receives $17.00 Consensus Target Price from Analysts

Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) have been assigned an average recommendation of “Moderate Buy” from the nine analysts that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $17.00.

ATEC has been the topic of several research reports. Morgan Stanley lowered shares of Alphatec from an “overweight” rating to an “equal weight” rating in a report on Thursday, August 1st. Wells Fargo & Company cut their price target on shares of Alphatec from $26.00 to $19.00 and set an “overweight” rating on the stock in a report on Thursday, August 1st. Piper Sandler cut their price target on shares of Alphatec from $17.00 to $12.00 and set an “overweight” rating on the stock in a report on Thursday, August 1st. Lake Street Capital cut their price target on shares of Alphatec from $32.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, September 3rd. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $13.00 price target on shares of Alphatec in a report on Thursday, October 31st.

Insider Activity at Alphatec

In other Alphatec news, Director David M. Demski acquired 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 21st. The stock was bought at an average price of $5.67 per share, with a total value of $283,500.00. Following the purchase, the director now owns 288,441 shares in the company, valued at approximately $1,635,460.47. The trade was a 20.97 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 22.80% of the stock is owned by corporate insiders.

Institutional Trading of Alphatec

Several large investors have recently bought and sold shares of ATEC. Barclays PLC grew its stake in shares of Alphatec by 362.3% in the 3rd quarter. Barclays PLC now owns 170,546 shares of the medical technology company’s stock valued at $948,000 after buying an additional 133,653 shares during the period. Y Intercept Hong Kong Ltd purchased a new stake in shares of Alphatec in the 3rd quarter valued at approximately $147,000. XTX Topco Ltd purchased a new stake in shares of Alphatec in the 3rd quarter valued at approximately $69,000. State Street Corp grew its stake in shares of Alphatec by 10.1% in the 3rd quarter. State Street Corp now owns 3,138,960 shares of the medical technology company’s stock valued at $17,453,000 after buying an additional 287,350 shares during the period. Finally, Stifel Financial Corp lifted its holdings in shares of Alphatec by 19.7% in the 3rd quarter. Stifel Financial Corp now owns 178,702 shares of the medical technology company’s stock worth $994,000 after acquiring an additional 29,411 shares during the last quarter. Hedge funds and other institutional investors own 66.35% of the company’s stock.

Alphatec Stock Performance

Alphatec stock opened at $8.23 on Friday. The company has a 50 day moving average price of $6.30 and a 200-day moving average price of $8.39. The company has a debt-to-equity ratio of 30.21, a quick ratio of 1.15 and a current ratio of 2.32. Alphatec has a fifty-two week low of $4.88 and a fifty-two week high of $17.34. The company has a market capitalization of $1.17 billion, a PE ratio of -6.43 and a beta of 1.31.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.